<DOC>
	<DOCNO>NCT01982955</DOCNO>
	<brief_summary>This multi-center , open-label , randomize , Phase 1b/2 trial determine recommend phase 2 dose ( RP2D ) evaluate efficacy term progression free survival ( PFS ) Tepotinib use combination gefitinib subject T790M negative , MET positive locally advanced metastatic non-small cell lung cancer ( NSCLC ) harbor epidermal growth factor receptor ( EGFR ) mutation acquire resistance Prior EGFR-Tyrosine Kinase Inhibitor ( EGFR-TKI ) Therapy . This study 2:1 randomization ( Tepotinib/Gefitinib arm versus Chemotherapy arm ) .</brief_summary>
	<brief_title>Tepotinib With Gefitinib Subjects With Locally Advanced Metastatic Non-small Cell Lung Cancer ( NSCLC )</brief_title>
	<detailed_description />
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Gefitinib</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<mesh_term>Pemetrexed</mesh_term>
	<criteria>Phase Ib Histologically cytologically confirm advanced nonsmall cell lung cancer ( NSCLC ) , regardless histology subtype , fail gefitinib reason toxicity compliance ; Availability fresh archived pre treatment tumor biopsy ( exclude fine needle aspiration cytology sample ) . For subject least 1 prior anticancer treatment , biopsy obtain failure recent anticancer treatment enrolment mandatory ; Mesenchymalepithelial transition diagnosticpositive ( status ) ( MET+ status ) , determined central laboratory Eastern Cooperative Oncology Group ( ECOG ) performance status ( PS ) 0 1 Other protocol define inclusion criterion could apply . Phase II Inclusion criterion : Locally advance metastatic NSCLC predominantly squamous histology ( confirm either histology cytology ) ; Activating mutation epidermal growth factor ( EGFR ) receptor ( document , determined central laboratory ) Acquired resistance firstline EGFRTyrosine Kinase Inhibitors ( EGFRTKI ) therapy include gefitinib , erlotinib , icotinib , afatinib EGFR T790M status acquire resistance first line EGFRTKI therapy include gefitinib , erlotinib , icotinib , afatinib treatment ( determined central laboratory , use validate PCR test ) ; T790M negative status randomize part T790M positive status singlearm cohort ( mainland China site ) Availability fresh archive tumor tissue ( exclude fine needle aspiration cytology sample ) obtain documentation acquire resistance gefitinib , erlotinib , icotinib , afatinib enrollment mandatory MET+ status , determine central laboratory i.e . cMet overexpression determine IHC ( i.e. , IHC 2+ IHC 3+ ) and/or cMet amplification and/or increase cMet gene copy number ( GCN ) , determine ISH ; Eastern Cooperative Oncology Group ( ECOG ) performance status 0 1 Other protocol define inclusion criterion could apply Exclusion Criteria ( Phase I II ) : Estimated life expectancy le ( &lt; ) 3 month Inadequate bone marrow , liver renal function Prior chemotherapy , biological therapy , radiation therapy , investigational anticancer therapy ( include palliative radiotherapy focal site ) within 21 day prior first dose trial treatment ( Phase 1b ) Prior systemic anticancer treatment chemotherapy agent target EGFR pathway exclude gefitinib , erlotinib , icotinib , afatinib advanced NSCLC ( one course chemotherapy regimen [ neo ] adjuvant purpose , one course chemoradiation Stage IIIa disease allow ) ( Phase 2 ) Other protocol define exclusion criterion could apply .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>MSC2156119J</keyword>
	<keyword>Gefitinib</keyword>
	<keyword>Pemetrexed</keyword>
	<keyword>Cisplatin</keyword>
	<keyword>MET positive</keyword>
	<keyword>Tepotinib</keyword>
	<keyword>Carboplatin</keyword>
	<keyword>INSIGHT</keyword>
</DOC>